Immitra Bio
Developer of a genetic medicine platform that combines hematopoietic stem cell manipulation and CRISPR-Cas9 gene editing to create precise and durable modifications in blood-forming stem cells for therapeutic development targeting rare diseases.
Industries
biotechnology
life-science
Nr. of Employees
small (1-50)
Products
Gene Therapy Platform Combining Hematopoietic Stem Cells and CRISPR-Cas9
A gene therapy platform that enables precise and durable gene modifications within blood stem cells to treat rare diseases.
Gene Therapy Platform Combining Hematopoietic Stem Cells and CRISPR-Cas9
A gene therapy platform that enables precise and durable gene modifications within blood stem cells to treat rare diseases.
Expertise Areas
- Hematopoietic stem cell gene editing
- Genetic medicine platform development
- Rare disease therapeutic development
- Preclinical translational research
Key Technologies
- CRISPR-Cas9 gene editing
- Hematopoietic stem cell manipulation
- Gene editing platform technologies
- Cell-based therapy methods